Very early researchNot Yet RecruitingNCT07458919What this trial is testingTherapy for Advanced NSCLC With EGFR 19delins MutationWho this might be right forLung Cancer Fuzhou General Hospital 94
Not applicableStudy completedNCT01208467What this trial is testingPrognostic Biomarkers in Patients With Endometrial CancerWho this might be right forEndometrial AdenocarcinomaRecurrent Uterine Corpus CarcinomaStage I Uterine Corpus Cancer+3 more Gynecologic Oncology Group 2,824
Very early researchUnknownNCT03728322What this trial is testingIHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia MutationsWho this might be right forThalassemia Allife Medical Science and Technology Co., Ltd. 12
Testing effectiveness (Phase 2)Ended earlyNCT04030429What this trial is testingCrizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial CancerWho this might be right forEndometrial Cancer Recurrent National Cheng-Kung University Hospital 40
Large-scale testing (Phase 3)Study completedNCT02616029What this trial is testingStudy to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184IWho this might be right forHIV-1 Infection Gilead Sciences 66
Not applicableStudy completedNCT02827357What this trial is testingResponses to Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 MutationWho this might be right forLung Cancer University Hospital, Toulouse 101
Testing effectiveness (Phase 2)Study completedNCT01260181What this trial is testingErlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor MutationsWho this might be right forNon-Squamous Non-Small Cell Lung Cancer Hoffmann-La Roche 30
Not applicableUnknownNCT03424772What this trial is testingWhole Genome Sequencing in the Detection of Rare Undiagnosed Genetic Diseases in Children in ChinaWho this might be right forIntellectual DisabilityMultiple Congenital AnomalyRare Diseases Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 100
Early research (Phase 1)Ended earlyNCT01611675What this trial is testingLeflunomide+Vemurafenib in V600 Mutant Met. MelanomaWho this might be right forMelanoma Massachusetts General Hospital 3
Not applicableStudy completedNCT04961619What this trial is testingAdjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.Who this might be right forMelanoma Novartis Pharmaceuticals 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167What this trial is testingTesting AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)Who this might be right forAdvanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more National Cancer Institute (NCI) 19
Not applicableStudy completedNCT01353300What this trial is testingGene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing CancerWho this might be right forBrain and Central Nervous System TumorsHereditary Wilms TumorKidney Cancer+4 more Children's Oncology Group 31
Not applicableUnknownNCT03224377What this trial is testingDiagnostic Utility of Anti MCV Antibodies,Anti CCPantibodies and RF in RAWho this might be right forRheumatoid Arthritis Assiut University 80
Testing effectiveness (Phase 2)Study completedNCT03037385What this trial is testingPhase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsWho this might be right forRET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more Hoffmann-La Roche 590
Testing effectiveness (Phase 2)UnknownNCT05135715What this trial is testingRC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)Who this might be right forMelanoma, Stage IIHER2-positiveAdvanced Melanoma RemeGen Co., Ltd. 50
Not applicableLooking for participantsNCT05848271What this trial is testingNatural History Study of Patients with HPDL MutationsWho this might be right forMitochondrial EncephalomyopathiesHereditary Spastic ParaplegiaSpastic Paraplegia+4 more University of California, San Diego 50
Testing effectiveness (Phase 2)Study completedNCT02952534What this trial is testingRucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyWho this might be right forMetastatic Castration Resistant Prostate Cancer pharmaand GmbH 277
Very early researchWithdrawnNCT06025032What this trial is testingA Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA Base-eDiting Therapy(SOUND)Who this might be right forCongenital Hearing Loss HuidaGene Therapeutics Co., Ltd.
Testing effectiveness (Phase 2)Study completedNCT03544814What this trial is testingEGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual ProgressionWho this might be right forLung AdenocarcinomaEGFR Activating Mutation Shanghai Chest Hospital 99
Not applicableStudy completedNCT05264532What this trial is testingUsefulness of Video-Based Intervention in Helping Participants Encourage Their Families to Get Tested for BRCA Gene MutationsWho this might be right forBRCA1 Gene MutationBRCA2 Gene Mutation Ohio State University Comprehensive Cancer Center 58